Cart
sales@molnova.com
HIF-2α-IN-3
CAS No. 313964-19-1
HIF-2α-IN-3( —— )
Catalog No. M32959 CAS No. 313964-19-1
HIF-2α-IN-3 is a HIF-2α alteration inhibitor with anti-tumor properties and may be used in the study of cardiovascular disease.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 178 | Get Quote |
|
| 5MG | 275 | Get Quote |
|
| 10MG | 432 | Get Quote |
|
| 25MG | 818 | Get Quote |
|
| 50MG | 1251 | Get Quote |
|
| 100MG | 1674 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameHIF-2α-IN-3
-
NoteResearch use only, not for human use.
-
Brief DescriptionHIF-2α-IN-3 is a HIF-2α alteration inhibitor with anti-tumor properties and may be used in the study of cardiovascular disease.
-
DescriptionHIF-2α-IN-3, an allosteric inhibitor of hypoxia inducible factor-2α (HIF-2α), exhibits an IC50 of 0.4 μM and a KD of 1.1 μM. Anticancer agent.
-
In VitroHIF-2α-IN-3 (Compound 1) inhibit HIF-2α-ARNT (also known as HIF-β) heterodimerization by binding an internal cavity of the HIF-2α PAS-B domain.
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetHIF/HIF Prolyl-hydroxylase
-
RecptorHIF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number313964-19-1
-
Formula Weight335.66
-
Molecular FormulaC12H6ClN5O5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 12.5 mg/mL (37.24 mM; Ultrasonic )
-
SMILES[O-][N+](=O)c1cc(Nc2ccc3nonc3c2[N+]([O-])=O)ccc1Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Rogers JL, et al. Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor. J Med Chem. 2013 Feb 28;56(4):1739-47.?
molnova catalog
related products
-
Adaptaquin
Adaptaquin is an inhibitor of the hypoxia-inducing factor prolyl hydroxylase (HIF-PH).
-
HIF1-IN-2
A potent, selective HIF-1 inhibitor with IC50 of 1.9 nM, with no signigicant inhibition on HSF and NF-κB.
-
BAY 87-2243
BAY 87-2243 is a potent and selective hypoxia-inducible factor-1 (HIF-1) inhibitor. Phase 1.
